We therefore suggest that future studies adopt PPOSTO2 act as a metric for hyperoxia assessment and concomitantly measure markers of gut injury (e.g., I-FABP), dysbiosis (e.g., Enterobacteriaceae) and metabolic disorders (e.g., SCFAs) to assess the potential negative impact of intestinal hyperoxia. The gene discussed is FABP2; the disease is metabolic disease.